Investment Rating - The investment rating for the chemical raw materials industry is optimistic (maintained) [1] Core Viewpoints - The refrigerant market continues its upward trend, with firm pricing observed [4][22] - The fluorochemical industry chain is entering a long-term prosperity cycle, with significant growth potential across various segments [22][23] Summary by Sections 1. Fluorochemical Industry Overview - The fluorochemical index increased by 1.4% during the week of June 30 to July 4, underperforming the Shanghai Composite Index by 0.002% and the CSI 300 Index by 0.14% [6][26] - The index closed at 4161.71 points, outperforming the basic chemical index by 0.73% and the new materials index by 0.12% [6][26] 2. Fluorspar Market - As of July 4, the average market price for 97% wet fluorite powder was 3,200 CNY/ton, down 2.88% from the previous week and down 13.61% year-on-year [7][33] - The market is experiencing a stalemate due to high inventory levels and weak demand, leading to a subdued trading atmosphere [19][34] 3. Refrigerant Market - As of July 4, refrigerant prices showed an upward trend: R32 at 53,000 CNY/ton (+0.95%), R125 at 45,500 CNY/ton (unchanged), R134a at 49,500 CNY/ton (+1.02%), R410a at 49,500 CNY/ton (+1.02%), and R22 at 35,000 CNY/ton (unchanged) [8][20][47] - The market for refrigerants remains stable, with companies raising prices to boost confidence despite seasonal demand challenges [21] 4. Beneficiary Companies - Recommended stocks include Jinshi Resources, Juhua Co., Sanmei Co., and Haohua Technology, with other beneficiaries being Dongyangguang, Yonghe Co., Dongyue Group, and Xinzhou Bang [10][22][23]

证券代码：600673 证券简称：东阳光 编号：临 2025-41 号 债券代码：242444 债券简称：25 东科 01 广东东阳光科技控股股份有限公司 关于 2022 年员工持股计划存续期即将届满的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广东东阳光科技控股股份有限公司（以下简称"公司"或"东阳光"）2022 年员工持股计划（以下简称"本次员工持股计划"）的存续期将于 2026 年 1 月 4 日届满。根据《关于上市公司实施员工持股计划试点的指导意见》《上海证券交 易所上市公司自律监管指引第 1 号—规范运作》等要求，上市公司应当在员工持 股计划届满前 6 个月公告到期计划持有的股票数量以及占公司股本总额的比例。 现将相关情况公告如下： 一、本次员工持股计划存续期的基本情况 公司于 2022 年 7 月 18 日、2022 年 8 月 15 日召开了第十一届董事会第十八 次会议和 2022 年第五次临时股东大会，审议并通过了《关于 <广东东阳光科技控> 股股份有限公司 2022 年员工持股计划（草案）>及 ...

| 证券代码：600673 | 证券简称：东阳光 | | 编号：临 2025-41 | 号 | | --- | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 东科 | 01 | | | 广东东阳光科技控股股份有限公司 关于 2022 年员工持股计划存续期即将届满的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广东东阳光科技控股股份有限公司（以下简称"公司"或"东阳光"）2022 年员工持股计划（以下简称"本次员工持股计划"）的存续期将于 2026 年 1 月 4 日届满。根据《关于上市公司实施员工持股计划试点的指导意见》《上海证券交 易所上市公司自律监管指引第 1 号—规范运作》等要求，上市公司应当在员工持 股计划届满前 6 个月公告到期计划持有的股票数量以及占公司股本总额的比例。 现将相关情况公告如下： 一、本次员工持股计划存续期的基本情况 公司于 2022 年 7 月 18 日、2022 年 8 月 15 日召开了第十一届董事会第十八 次会议和 2022 年第 ...

Core Viewpoint - Dongyangguang Pharmaceutical Co., Ltd. is set to return to the capital market with a new positioning as an innovative pharmaceutical company through a "introduction listing" on the Hong Kong Stock Exchange, aiming to list 112.7 million H shares by August 7, 2025, following its privatization [1] Group 1: Company Transformation and R&D Focus - The company has successfully transformed by focusing on innovative drug research and development, showcasing resilience and growth [1] - Dongyangguang has established the only national key laboratory for the research and development of new anti-infection drugs in Guangdong Province, equipped with over 50,000 square meters of laboratory space and more than 400 high-performance liquid chromatography instruments [1] - The company has maintained a high investment in R&D, with over 20% of its revenue allocated to R&D in 2024, leading to breakthroughs in core technologies and breaking foreign technology monopolies [2] Group 2: Innovation and AI Integration - Dongyangguang ranks first among domestic pharmaceutical companies in the number of patents published and granted in China from 2014 to 2023 [2] - The company is actively integrating AI technology to enhance R&D efficiency, with the first candidate drug HEC169584 developed through an AI-driven platform currently in clinical trials [2] Group 3: Organizational Culture and Competitive Advantage - The company emphasizes expert-led decision-making and team practices to build core competencies, allowing experts to focus on technical areas without administrative duties [3] - The organizational culture, established by founder Zhang Zhongneng, promotes resilience and confidence, which has helped attract and motivate talent [3] - Dongyangguang has developed a mature system covering three major fields and the entire R&D lifecycle, achieving a leap towards "systematic innovation" [3]

（原标题：综合行业7月1日资金流向日报） 综合行业资金流向排名 沪指7月1日上涨0.39%，申万所属行业中，今日上涨的有20个，涨幅居前的行业为综合、医药生物，涨 幅分别为2.60%、1.80%。综合行业位居今日涨幅榜首位。跌幅居前的行业为计算机、商贸零售，跌幅 分别为1.18%、0.79%。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 综合行业今日上涨2.60%，全天主力资金净流入1.22亿元，该行业所属的个股共19只，今日上涨的有11 只；下跌的有4只。以资金流向数据进行统计，该行业资金净流入的个股有7只，净流入资金居首的是东 阳光，今日净流入资金1.58亿元，紧随其后的是综艺股份、漳州发展，净流入资金分别为1667.03万元、 450.88万元。综合行业资金净流出个股中，净流出资金居前的有粤桂股份、宁波联合、南京公用，净流 出资金分别为1120.78万元、936.84万元、888.45万元。（数据宝） | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 600673 | 东阳光 ...

Core Viewpoint - The Hong Kong stock market is experiencing a wave of value reassessment for innovative drugs, with investors increasingly favoring benchmark pharmaceutical companies with "investment certainty" [1][4] Group 1: Company Overview - Dongyangguang Pharmaceutical, a leading company in the domestic biopharmaceutical sector, is set to list on the Hong Kong stock market, which is seen as a positive development for investors [1] - The company announced on June 27 that the privatization proposal to absorb and merge with Dongyangguang Changjiang Pharmaceutical has met all preliminary conditions [1][4] - The listing process has entered its final waiting period, with H-shares expected to begin trading on August 7, 2024, under the new stock code "06887" [4] Group 2: Listing Strategy - Dongyangguang Pharmaceutical's listing strategy involves a "merger of subsidiaries + introduction" approach, which is a first in the Hong Kong market, emphasizing the company's commitment to protecting shareholder rights [4][5] - The introduction method does not involve new share issuance or fundraising, indicating a focus on maintaining existing shareholder equity [5][6] Group 3: Financial Health - The company reported a revenue of 3.724 billion yuan and held cash and cash equivalents of 1.48 billion yuan in 2024, indicating a strong financial position [5] - The robust cash flow and revenue support the company's innovative research and development efforts, providing a solid foundation for its listing strategy [5] Group 4: Research and Development - Dongyangguang Pharmaceutical has established a competitive R&D platform with over 1,100 professionals, covering the entire lifecycle of drug development [7] - The company has 150 drugs globally and over 100 in development, including 49 first-class innovative drugs, with three already under review for market approval in China [7][9] - The company has applied for 2,446 invention patents, with 1,401 granted, ranking first among domestic pharmaceutical companies in patent filings from 2014 to 2023 [7] Group 5: Market Potential - The company has entered into a significant licensing agreement worth $938 million for its FGF21/GLP-1 dual-specific fusion protein, setting a record for domestic BD transactions [9] - The drug candidate Ifenprodil, currently in Phase III clinical trials, shows potential for significant market impact due to its superior efficacy compared to existing treatments [9][10] - The integration of AI technology into the drug development process is expected to enhance innovation efficiency and success rates [10] Group 6: Investment Outlook - In the current market environment favoring "more certain enterprises," Dongyangguang Pharmaceutical is positioned as a high-value biopharmaceutical investment target, with its innovative drug assets and AI capabilities likely to attract market recognition post-listing [11]

Core Viewpoint - Dongyang Sunshine Pharmaceutical is pursuing a unique "zero fundraising IPO" strategy by merging with its subsidiary Dongyang Sunshine Changjiang Pharmaceutical, aiming to enhance its competitive position in the pharmaceutical industry [2][3]. Group 1: Listing Strategy - The company plans to go public in Hong Kong through a merger with its subsidiary, which will involve issuing H-shares to shareholders without raising new funds [3]. - This unconventional approach is intended to consolidate its pharmaceutical assets and create a comprehensive pharmaceutical company that integrates R&D, production, and commercialization [3]. Group 2: Market Position - Dongyang Sunshine Pharmaceutical holds a dominant position in the domestic market for its core product, Oseltamivir Phosphate, ranking first in 2024 [2]. - The sales contribution of Oseltamivir Phosphate to total revenue has fluctuated but remains a crucial support for the company's performance from 2022 to 2024 [2]. Group 3: R&D and Innovation - The company has established a robust R&D platform with over 1,100 professionals, focusing on various therapeutic areas including infections, chronic diseases, and oncology [8]. - Dongyang Sunshine has a diverse portfolio of over 150 approved drugs and more than 100 drugs in development, with 49 first-class innovative drugs [8][9]. - The company has invested significantly in R&D, with expenditures of 792 million yuan, 827 million yuan, and 888 million yuan from 2022 to 2024, representing 20.8%, 13.0%, and 22.1% of total revenue respectively [9]. Group 4: Business Development (BD) Collaborations - The company is actively engaging in BD collaborations to expand its commercialization pathways, including a notable agreement with Apollo Therapeutics valued at $938 million for a dual-specific fusion protein [6][7]. - Dongyang Sunshine is one of the few Chinese pharmaceutical companies developing insulin products for the U.S. market, showcasing its global resource integration capabilities [7]. Group 5: AI Technology in R&D - The company is leveraging AI technology across various stages of drug development, having established multiple advanced AI-driven models to enhance innovation and efficiency [9]. - A recent AI-driven first-class new drug, HEC169584, has been approved for clinical trials targeting non-alcoholic fatty liver disease (NASH) [9].

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) has applied for the listing and trading of 112.7 million H-shares on the Hong Kong Stock Exchange, based on the assumption that all shareholders will convert their shares according to the exchange ratio and merger agreement [1][2] Group 1 - The company plans to privatize Dongyang Sunshine Changjiang Pharmaceutical by issuing H-shares as consideration to acquire the H-shares held by shareholders, with a conversion ratio of 0.263614 new H-shares for each H-share of Dongyang Sunshine Changjiang Pharmaceutical [2] - A special dividend of HKD 1.50 per share will be paid to shareholders of Dongyang Sunshine Changjiang Pharmaceutical, who collectively hold approximately 427.6 million shares, upon the completion of the privatization [2] - Upon completion of the privatization, Dongyang Sunshine Changjiang Pharmaceutical's listing status on the exchange will be revoked, and the company will assume all assets, liabilities, and rights of Dongyang Sunshine Changjiang Pharmaceutical [2] Group 2 - The H-shares will be eligible securities for Hong Kong clearing once approved for listing and trading, allowing for deposit, settlement, and transfer in the central clearing system [3]

Core Viewpoint - The launch of the new brand "Dongyangguang Bujiyi" by Dongyangguang Group aims to promote the consumption of Cordyceps sinensis, making it accessible to the general public and enhancing the health of the nation through traditional Chinese medicinal practices [1][9][13] Industry Overview - The health management awareness among the public is increasing, with the demand for Cordyceps sinensis supplements rising due to the implementation of health strategies like "Healthy China 2030" [3] - The scale of China's health industry is expected to reach 16 trillion yuan by 2030, with the Cordyceps industry projected to exceed 100 billion yuan [3] - The shift in public health needs from "single treatment" to "integrated treatment and nourishment" reflects a broader trend towards daily health maintenance [3] Company Strategy - Dongyangguang Group has invested over 4 billion yuan and employed over 260 researchers since 2007 to develop ecological breeding for Cordyceps sinensis, achieving industrialization and standardization [3][5] - The company has established a nearly 400,000 square meter ecological breeding base in Yidu, Hubei, capable of producing 60 tons annually, ensuring year-round supply [6] Product Development - The new brand "Dongyangguang Bujiyi" focuses on providing affordable and high-quality Cordyceps products, with eight new products designed for various daily health needs [9] - The brand emphasizes quality control through a design-based quality management approach, ensuring products are free from additives and contaminants [11] Market Positioning - Dongyangguang Group's previous high-end brand "Dongyangguang Fresh Cordyceps" has gained recognition in the market, winning awards and promoting a new trend in traditional Chinese nourishment [7] - The launch of "Dongyangguang Bujiyi" is expected to democratize the Cordyceps market, making it a preferred choice for national health and promoting Chinese medicinal culture globally [13]

Core Viewpoint - The transformation of traditional Chinese pharmaceutical companies towards innovation is gaining momentum, exemplified by Dongyang Sunshine Pharmaceutical's IPO application and its focus on innovative drug development [1][2]. Group 1: Innovation Transformation - Dongyang Sunshine Pharmaceutical has accumulated over 20 years of research and development experience, owning 150 approved drugs across China, the US, and Europe, which provides a solid foundation for its innovative R&D [2]. - The company plans to invest 7.92 billion RMB, 8.27 billion RMB, and 8.88 billion RMB in R&D from 2022 to 2024, representing 20.8%, 13.0%, and 22.1% of total revenue respectively, indicating a commitment to high R&D spending [2]. - Dongyang Sunshine has a complete production line from raw materials to formulations, with leading facilities for solid formulations and biopharmaceuticals, and has received multiple GMP certifications in China, the US, and Europe [2]. Group 2: Sales and Distribution - The company has a large sales and distribution network with nearly 2,000 sales professionals, covering 32 provincial administrative regions and over 25,000 hospitals in China [3]. - Dongyang Sunshine is positioned to be one of the first Chinese pharmaceutical companies to obtain approval for insulin in the US, expanding its global market reach [3]. Group 3: Product Pipeline and Clinical Development - Dongyang Sunshine has successfully launched three innovative hepatitis C drugs and is expanding its pipeline to include a SGLT-2 oral diabetes drug and over ten new drugs in II and III phase clinical trials targeting various diseases [3][9]. - The company is focusing on oncology, with over 20 innovative pipelines, including the FLT3 inhibitor, Clifofitinib, which is currently in III phase clinical trials for acute myeloid leukemia (AML) [4][5]. Group 4: Market Potential - Clifofitinib has a global sales peak potential of 1 billion USD, with an expected annual sales peak of 3-4 billion RMB in China, highlighting its significant market opportunity [8]. - The company has established a commercial partnership for Clifofitinib with Shenyang Sanofi Pharmaceutical to enhance market penetration upon its launch [8]. Group 5: Future Outlook - Dongyang Sunshine is redefining its innovation boundaries, transitioning from a "flu expert" to a globally competitive innovative pharmaceutical company, with a focus on advanced technologies such as AI in drug development [11][12]. - The company aims to continue breakthroughs in metabolic diseases, anti-infection, and oncology, potentially becoming a benchmark for innovation transformation among local pharmaceutical companies [12].